Medarex seem to be the more aggressive of the twins at present. At least PR-wise. There is a fairly "exhaustive" interview with Drakeman on Motley Fool. It deals mainly with the company's business model, but he is also touching on products they already have in development.
Judging from the recruitments announced yesterday, the time has now come for them to start putting a lot more effort into the clinical side of their business.
>>PRINCETON, N.J., Nov. 6 /PRNewswire/ -- Medarex, Inc. (Nasdaq: MEDX - news) today announced additions to its clinical department with the appointments of Thomas A. Davis, M.D. as Director of Clinical Science; Michael J. Yellin, M.D. as Director of Rheumatology and Immunology; and Richard S. Romasz, Ph.D. as Director of Clinical Operations. Dr. Davis and Dr. Yellin will be responsible for clinical strategy development and clinical trial design. Dr. Romasz will oversee the conduct of clinical trials, including protocol preparations, study monitoring, data evaluation and application submissions. They are supported by a team of clinical study managers, clinical research assistants, medical writers and other staff needed to conduct the widening range of clinical programs at Medarex.>>
The interview on MTF can be found at the following URL:
boards.fool.com
For those who are not registered at TMF and don't intend to register, there is also a copy available at the RB Medarex board.
ragingbull.lycos.com
Ice |
